Directly, GA suppresses tumor cell viability by targeting oncogenic pathways: in cholangiocarcinoma, it inhibits the AKT/mTOR axis to induce apoptotic cell death (212), a mechanism that complements its immune-modulatory actions by reducing tumor burden and limiting TME inflammation-driven immunosuppression. This evidence concerns the gene AKT1 and neoplasm.